Suche senden
Hochladen
Intracoronary Bone Marrow Mononuclear Cells After Myocardial Infarction
âą
1 gefÀllt mir
âą
435 views
ProActive Capital Resources Group
Folgen
ntracoronary Bone Marrow Mononuclear Cells After Myocardial Infarction
Weniger lesen
Mehr lesen
Investorbeziehungen
Gesundheit & Medizin
Technologie
Melden
Teilen
Melden
Teilen
1 von 3
Jetzt herunterladen
Downloaden Sie, um offline zu lesen
Empfohlen
Daily Dose Equities - Intracoronary Bone Marrow
Daily Dose Equities - Intracoronary Bone Marrow
ProActive Capital Resources Group
Â
Daily Dose Equities - Effect of Transendocardial Delivery
Daily Dose Equities - Effect of Transendocardial Delivery
ProActive Capital Resources Group
Â
Intramyocardial Angiogenic Cell Precursors in Non-Ischemic Dilated Cardiomyop...
Intramyocardial Angiogenic Cell Precursors in Non-Ischemic Dilated Cardiomyop...
lifextechnologies
Â
Okyanos Heart Institute
Okyanos Heart Institute
Erika Rosenthal
Â
Cardiac MRI in hypertrophic cardiomyopathy
Cardiac MRI in hypertrophic cardiomyopathy
Adolfo Aliaga Quezada
Â
Nanomedicina5
Nanomedicina5
joanamatux
Â
Risco cardiovascular em_pacientes_hiv_
Risco cardiovascular em_pacientes_hiv_
gisa_legal
Â
Current stem cell delivery methods for myocardial repair
Current stem cell delivery methods for myocardial repair
R.Harish Kumar
Â
Empfohlen
Daily Dose Equities - Intracoronary Bone Marrow
Daily Dose Equities - Intracoronary Bone Marrow
ProActive Capital Resources Group
Â
Daily Dose Equities - Effect of Transendocardial Delivery
Daily Dose Equities - Effect of Transendocardial Delivery
ProActive Capital Resources Group
Â
Intramyocardial Angiogenic Cell Precursors in Non-Ischemic Dilated Cardiomyop...
Intramyocardial Angiogenic Cell Precursors in Non-Ischemic Dilated Cardiomyop...
lifextechnologies
Â
Okyanos Heart Institute
Okyanos Heart Institute
Erika Rosenthal
Â
Cardiac MRI in hypertrophic cardiomyopathy
Cardiac MRI in hypertrophic cardiomyopathy
Adolfo Aliaga Quezada
Â
Nanomedicina5
Nanomedicina5
joanamatux
Â
Risco cardiovascular em_pacientes_hiv_
Risco cardiovascular em_pacientes_hiv_
gisa_legal
Â
Current stem cell delivery methods for myocardial repair
Current stem cell delivery methods for myocardial repair
R.Harish Kumar
Â
Stich ii trial for supratentorial intra cerebral bleed
Stich ii trial for supratentorial intra cerebral bleed
garry07
Â
Management of Takotsubo Syndrome: A Comprehensive Review
Management of Takotsubo Syndrome: A Comprehensive Review
Nicolas Ugarte
Â
Circulation Journal
Circulation Journal
Taruna Ikrar
Â
journal club ccsvi
journal club ccsvi
Neurology resident slides
Â
In stent retenosis pathophysiology
In stent retenosis pathophysiology
Nilesh Tawade
Â
Bioabsorbable Drug-Eluting Cardiac Stent Analysis
Bioabsorbable Drug-Eluting Cardiac Stent Analysis
University of Toronto
Â
Radiological pathology of transient ischemic attacks
Radiological pathology of transient ischemic attacks
Professor Yasser Metwally
Â
Cell therapy in cardiovascular diseases
Cell therapy in cardiovascular diseases
The department of Cardiovascular medicine.
Â
Gene expression and IVUS
Gene expression and IVUS
Cardiovascular Diagnosis and Therapy (CDT)
Â
Problem associated with drug eluting stent
Problem associated with drug eluting stent
PRAVEEN GUPTA
Â
Toast criteria
Toast criteria
RSUD Indramayu
Â
Use of TEGÂź in Acute Traumatic Brain Injury
Use of TEGÂź in Acute Traumatic Brain Injury
kathleenmccann
Â
Advanced Journal of Vascular Medicine
Advanced Journal of Vascular Medicine
SciRes Literature LLC. | Open Access Journals
Â
Hirayama jc
Hirayama jc
Neurology resident slides
Â
Profilaxis en pacientes quirurgicos
Profilaxis en pacientes quirurgicos
Anderson David
Â
Coronary Stent thrombosis,comparisons between stents.Bioreabsorbable vascular...
Coronary Stent thrombosis,comparisons between stents.Bioreabsorbable vascular...
Dr.Hasan Mahmud
Â
In stent restenosis
In stent restenosis
Sahar Gamal
Â
Journal of Stem Cell Research and Transplantation
Journal of Stem Cell Research and Transplantation
Austin Publishing Group
Â
Columbia-Research
Columbia-Research
Anya Ragnhildstveit
Â
Heart disease research articles
Heart disease research articles
udankresey
Â
ART CART Artists
ART CART Artists
ARTCART
Â
Bioheart (OTC: BHRT; Twitter: $BHRT)
Bioheart (OTC: BHRT; Twitter: $BHRT)
ProActive Capital Resources Group
Â
Weitere Àhnliche Inhalte
Was ist angesagt?
Stich ii trial for supratentorial intra cerebral bleed
Stich ii trial for supratentorial intra cerebral bleed
garry07
Â
Management of Takotsubo Syndrome: A Comprehensive Review
Management of Takotsubo Syndrome: A Comprehensive Review
Nicolas Ugarte
Â
Circulation Journal
Circulation Journal
Taruna Ikrar
Â
journal club ccsvi
journal club ccsvi
Neurology resident slides
Â
In stent retenosis pathophysiology
In stent retenosis pathophysiology
Nilesh Tawade
Â
Bioabsorbable Drug-Eluting Cardiac Stent Analysis
Bioabsorbable Drug-Eluting Cardiac Stent Analysis
University of Toronto
Â
Radiological pathology of transient ischemic attacks
Radiological pathology of transient ischemic attacks
Professor Yasser Metwally
Â
Cell therapy in cardiovascular diseases
Cell therapy in cardiovascular diseases
The department of Cardiovascular medicine.
Â
Gene expression and IVUS
Gene expression and IVUS
Cardiovascular Diagnosis and Therapy (CDT)
Â
Problem associated with drug eluting stent
Problem associated with drug eluting stent
PRAVEEN GUPTA
Â
Toast criteria
Toast criteria
RSUD Indramayu
Â
Use of TEGÂź in Acute Traumatic Brain Injury
Use of TEGÂź in Acute Traumatic Brain Injury
kathleenmccann
Â
Advanced Journal of Vascular Medicine
Advanced Journal of Vascular Medicine
SciRes Literature LLC. | Open Access Journals
Â
Hirayama jc
Hirayama jc
Neurology resident slides
Â
Profilaxis en pacientes quirurgicos
Profilaxis en pacientes quirurgicos
Anderson David
Â
Coronary Stent thrombosis,comparisons between stents.Bioreabsorbable vascular...
Coronary Stent thrombosis,comparisons between stents.Bioreabsorbable vascular...
Dr.Hasan Mahmud
Â
In stent restenosis
In stent restenosis
Sahar Gamal
Â
Journal of Stem Cell Research and Transplantation
Journal of Stem Cell Research and Transplantation
Austin Publishing Group
Â
Columbia-Research
Columbia-Research
Anya Ragnhildstveit
Â
Heart disease research articles
Heart disease research articles
udankresey
Â
Was ist angesagt?
(20)
Stich ii trial for supratentorial intra cerebral bleed
Stich ii trial for supratentorial intra cerebral bleed
Â
Management of Takotsubo Syndrome: A Comprehensive Review
Management of Takotsubo Syndrome: A Comprehensive Review
Â
Circulation Journal
Circulation Journal
Â
journal club ccsvi
journal club ccsvi
Â
In stent retenosis pathophysiology
In stent retenosis pathophysiology
Â
Bioabsorbable Drug-Eluting Cardiac Stent Analysis
Bioabsorbable Drug-Eluting Cardiac Stent Analysis
Â
Radiological pathology of transient ischemic attacks
Radiological pathology of transient ischemic attacks
Â
Cell therapy in cardiovascular diseases
Cell therapy in cardiovascular diseases
Â
Gene expression and IVUS
Gene expression and IVUS
Â
Problem associated with drug eluting stent
Problem associated with drug eluting stent
Â
Toast criteria
Toast criteria
Â
Use of TEGÂź in Acute Traumatic Brain Injury
Use of TEGÂź in Acute Traumatic Brain Injury
Â
Advanced Journal of Vascular Medicine
Advanced Journal of Vascular Medicine
Â
Hirayama jc
Hirayama jc
Â
Profilaxis en pacientes quirurgicos
Profilaxis en pacientes quirurgicos
Â
Coronary Stent thrombosis,comparisons between stents.Bioreabsorbable vascular...
Coronary Stent thrombosis,comparisons between stents.Bioreabsorbable vascular...
Â
In stent restenosis
In stent restenosis
Â
Journal of Stem Cell Research and Transplantation
Journal of Stem Cell Research and Transplantation
Â
Columbia-Research
Columbia-Research
Â
Heart disease research articles
Heart disease research articles
Â
Andere mochten auch
ART CART Artists
ART CART Artists
ARTCART
Â
Bioheart (OTC: BHRT; Twitter: $BHRT)
Bioheart (OTC: BHRT; Twitter: $BHRT)
ProActive Capital Resources Group
Â
Emulsja grunt gotowa do uzycia
Emulsja grunt gotowa do uzycia
robertartois
Â
Cgs ve365 core presentation v4 july2010 copy
Cgs ve365 core presentation v4 july2010 copy
jhmcclain
Â
26
26
Kelly Dias
Â
HCP Radiology & Imaging 2011 Pictures
HCP Radiology & Imaging 2011 Pictures
Block Imaging
Â
Connected Commerce - Marketingplan 2015
Connected Commerce - Marketingplan 2015
Jaap van Oort
Â
Ensurge, Inc. (OTCBB: ESGI; Twitter: $ESGI)
Ensurge, Inc. (OTCBB: ESGI; Twitter: $ESGI)
ProActive Capital Resources Group
Â
LXXVIII
LXXVIII
fanny629
Â
Cormedix ($CRMD) - Maxim June 2011 Update
Cormedix ($CRMD) - Maxim June 2011 Update
ProActive Capital Resources Group
Â
Hien phap my duoc lam ra nhu the nao nguyen canh binh
Hien phap my duoc lam ra nhu the nao nguyen canh binh
Nguyen Tuan
Â
ĐĐĐĐĐĐŁĐ ~ Sponsorship Blogpool of the Cycling Club Gorski
ĐĐĐĐĐĐŁĐ ~ Sponsorship Blogpool of the Cycling Club Gorski
ĐĐžŃĐžĐșлОŃŃĐžŃĐșĐž ĐșĐ»Ńб ĐĐĐ ĐĄĐĐ
Â
AnquiloglĂČssia
AnquiloglĂČssia
soniaacademia02
Â
Aviation
Aviation
abhayraichand
Â
Teknik menghasilkan blog 1
Teknik menghasilkan blog 1
Roiamah Basri
Â
AVReporter Application of energy management solutions in logistics centers
AVReporter Application of energy management solutions in logistics centers
Avreporter KONsys
Â
Analisis penilaian
Analisis penilaian
Naya Ti
Â
Dog racing
Dog racing
Randy Kha
Â
Neostem, Inc. ($NBS) - WBB Securities Report
Neostem, Inc. ($NBS) - WBB Securities Report
ProActive Capital Resources Group
Â
èź©H5饔éąéé 移ćšèźŸć€ć šćź¶ - èźŸèźĄćžçŻ
èź©H5饔éąéé 移ćšèźŸć€ć šćź¶ - èźŸèźĄćžçŻ
peun zhang
Â
Andere mochten auch
(20)
ART CART Artists
ART CART Artists
Â
Bioheart (OTC: BHRT; Twitter: $BHRT)
Bioheart (OTC: BHRT; Twitter: $BHRT)
Â
Emulsja grunt gotowa do uzycia
Emulsja grunt gotowa do uzycia
Â
Cgs ve365 core presentation v4 july2010 copy
Cgs ve365 core presentation v4 july2010 copy
Â
26
26
Â
HCP Radiology & Imaging 2011 Pictures
HCP Radiology & Imaging 2011 Pictures
Â
Connected Commerce - Marketingplan 2015
Connected Commerce - Marketingplan 2015
Â
Ensurge, Inc. (OTCBB: ESGI; Twitter: $ESGI)
Ensurge, Inc. (OTCBB: ESGI; Twitter: $ESGI)
Â
LXXVIII
LXXVIII
Â
Cormedix ($CRMD) - Maxim June 2011 Update
Cormedix ($CRMD) - Maxim June 2011 Update
Â
Hien phap my duoc lam ra nhu the nao nguyen canh binh
Hien phap my duoc lam ra nhu the nao nguyen canh binh
Â
ĐĐĐĐĐĐŁĐ ~ Sponsorship Blogpool of the Cycling Club Gorski
ĐĐĐĐĐĐŁĐ ~ Sponsorship Blogpool of the Cycling Club Gorski
Â
AnquiloglĂČssia
AnquiloglĂČssia
Â
Aviation
Aviation
Â
Teknik menghasilkan blog 1
Teknik menghasilkan blog 1
Â
AVReporter Application of energy management solutions in logistics centers
AVReporter Application of energy management solutions in logistics centers
Â
Analisis penilaian
Analisis penilaian
Â
Dog racing
Dog racing
Â
Neostem, Inc. ($NBS) - WBB Securities Report
Neostem, Inc. ($NBS) - WBB Securities Report
Â
èź©H5饔éąéé 移ćšèźŸć€ć šćź¶ - èźŸèźĄćžçŻ
èź©H5饔éąéé 移ćšèźŸć€ć šćź¶ - èźŸèźĄćžçŻ
Â
Ăhnlich wie Intracoronary Bone Marrow Mononuclear Cells After Myocardial Infarction
Cell therapies in heart failure thet don't work
Cell therapies in heart failure thet don't work
drucsamal
Â
Stem cell transplantation for heart failure
Stem cell transplantation for heart failure
Ramachandra Barik
Â
ClinicalOutcomesFollowingCoronary BifurcationPCITechniques.pdf
ClinicalOutcomesFollowingCoronary BifurcationPCITechniques.pdf
Irving Torres Lopez
Â
Stem cells in cardiac care
Stem cells in cardiac care
BALASUBRAMANIAM IYER
Â
Stem cell
Stem cell
Mohammad Arifur Rahman
Â
Stitch trial
Stitch trial
auriom
Â
Dr Dake presentation ICCCV nov 2011
Dr Dake presentation ICCCV nov 2011
Sylvie Tuslanes
Â
1428931228
1428931228
Sanjay2176
Â
condiuts in Coronary artery bypass grafting
condiuts in Coronary artery bypass grafting
Ram Prassath
Â
Presentation1.pptx
Presentation1.pptx
purraSameer
Â
Revascularization for Ischemic Ventricular Dysfunction - REVIVED-BCIS2.pptx
Revascularization for Ischemic Ventricular Dysfunction - REVIVED-BCIS2.pptx
SpandanaRallapalli
Â
Production of stem cell derived cardiomyocytes
Production of stem cell derived cardiomyocytes
Md. Shabab Mehebub
Â
23
23
Nikko Nugraha
Â
Medcrave Group - Heart transplantation
Medcrave Group - Heart transplantation
MedCrave
Â
PPT Cath GAR 2.pptx
PPT Cath GAR 2.pptx
ssusera752fd
Â
Cardiac pacemakers part-II
Cardiac pacemakers part-II
Ramachandra Barik
Â
Cardiac CT Angiography to detect Myocardial Bridging
Cardiac CT Angiography to detect Myocardial Bridging
Han Naung Tun
Â
Ventricular arterial coupling
Ventricular arterial coupling
Ramachandra Barik
Â
Stem Cells - Biology ppt slides
Stem Cells - Biology ppt slides
nihattt
Â
Use of autologous skeletal myoblasts in cellular cardiomyoplasty
Use of autologous skeletal myoblasts in cellular cardiomyoplasty
Juan de Dios DĂaz Rosales
Â
Ăhnlich wie Intracoronary Bone Marrow Mononuclear Cells After Myocardial Infarction
(20)
Cell therapies in heart failure thet don't work
Cell therapies in heart failure thet don't work
Â
Stem cell transplantation for heart failure
Stem cell transplantation for heart failure
Â
ClinicalOutcomesFollowingCoronary BifurcationPCITechniques.pdf
ClinicalOutcomesFollowingCoronary BifurcationPCITechniques.pdf
Â
Stem cells in cardiac care
Stem cells in cardiac care
Â
Stem cell
Stem cell
Â
Stitch trial
Stitch trial
Â
Dr Dake presentation ICCCV nov 2011
Dr Dake presentation ICCCV nov 2011
Â
1428931228
1428931228
Â
condiuts in Coronary artery bypass grafting
condiuts in Coronary artery bypass grafting
Â
Presentation1.pptx
Presentation1.pptx
Â
Revascularization for Ischemic Ventricular Dysfunction - REVIVED-BCIS2.pptx
Revascularization for Ischemic Ventricular Dysfunction - REVIVED-BCIS2.pptx
Â
Production of stem cell derived cardiomyocytes
Production of stem cell derived cardiomyocytes
Â
23
23
Â
Medcrave Group - Heart transplantation
Medcrave Group - Heart transplantation
Â
PPT Cath GAR 2.pptx
PPT Cath GAR 2.pptx
Â
Cardiac pacemakers part-II
Cardiac pacemakers part-II
Â
Cardiac CT Angiography to detect Myocardial Bridging
Cardiac CT Angiography to detect Myocardial Bridging
Â
Ventricular arterial coupling
Ventricular arterial coupling
Â
Stem Cells - Biology ppt slides
Stem Cells - Biology ppt slides
Â
Use of autologous skeletal myoblasts in cellular cardiomyoplasty
Use of autologous skeletal myoblasts in cellular cardiomyoplasty
Â
Mehr von ProActive Capital Resources Group
Pegasi Energy Research Note July 18, 2012
Pegasi Energy Research Note July 18, 2012
ProActive Capital Resources Group
Â
Islet defense in bio century week of 5 28-12
Islet defense in bio century week of 5 28-12
ProActive Capital Resources Group
Â
Insider transaction detail for Isa Odidi (IPCI)
Insider transaction detail for Isa Odidi (IPCI)
ProActive Capital Resources Group
Â
Caprock risk management, llc
Caprock risk management, llc
ProActive Capital Resources Group
Â
VTUS SEC Filing Form 8-K
VTUS SEC Filing Form 8-K
ProActive Capital Resources Group
Â
TNXP Fact Sheet May 2012
TNXP Fact Sheet May 2012
ProActive Capital Resources Group
Â
Arcis Exec Summary
Arcis Exec Summary
ProActive Capital Resources Group
Â
SSIE 4.20.12
SSIE 4.20.12
ProActive Capital Resources Group
Â
Kerx zerenex phase3
Kerx zerenex phase3
ProActive Capital Resources Group
Â
ARM Stroke
ARM Stroke
ProActive Capital Resources Group
Â
ARM Parkinsons
ARM Parkinsons
ProActive Capital Resources Group
Â
ARM Heart Disease
ARM Heart Disease
ProActive Capital Resources Group
Â
ARM Diabetes
ARM Diabetes
ProActive Capital Resources Group
Â
Arm ALS
Arm ALS
ProActive Capital Resources Group
Â
Tonix12 ceocfo-article-clean newphoto
Tonix12 ceocfo-article-clean newphoto
ProActive Capital Resources Group
Â
Applied DNA Sciences (OTCBB: APDN)
Applied DNA Sciences (OTCBB: APDN)
ProActive Capital Resources Group
Â
Daily Dose Equities - Exosomes from human cd34
Daily Dose Equities - Exosomes from human cd34
ProActive Capital Resources Group
Â
2012 MHCC Web resentation proposal-3-19-2012-published
2012 MHCC Web resentation proposal-3-19-2012-published
ProActive Capital Resources Group
Â
PolyMedix ($PYMX) Cowan Research
PolyMedix ($PYMX) Cowan Research
ProActive Capital Resources Group
Â
VTUS Cowen Final March 2012
VTUS Cowen Final March 2012
ProActive Capital Resources Group
Â
Mehr von ProActive Capital Resources Group
(20)
Pegasi Energy Research Note July 18, 2012
Pegasi Energy Research Note July 18, 2012
Â
Islet defense in bio century week of 5 28-12
Islet defense in bio century week of 5 28-12
Â
Insider transaction detail for Isa Odidi (IPCI)
Insider transaction detail for Isa Odidi (IPCI)
Â
Caprock risk management, llc
Caprock risk management, llc
Â
VTUS SEC Filing Form 8-K
VTUS SEC Filing Form 8-K
Â
TNXP Fact Sheet May 2012
TNXP Fact Sheet May 2012
Â
Arcis Exec Summary
Arcis Exec Summary
Â
SSIE 4.20.12
SSIE 4.20.12
Â
Kerx zerenex phase3
Kerx zerenex phase3
Â
ARM Stroke
ARM Stroke
Â
ARM Parkinsons
ARM Parkinsons
Â
ARM Heart Disease
ARM Heart Disease
Â
ARM Diabetes
ARM Diabetes
Â
Arm ALS
Arm ALS
Â
Tonix12 ceocfo-article-clean newphoto
Tonix12 ceocfo-article-clean newphoto
Â
Applied DNA Sciences (OTCBB: APDN)
Applied DNA Sciences (OTCBB: APDN)
Â
Daily Dose Equities - Exosomes from human cd34
Daily Dose Equities - Exosomes from human cd34
Â
2012 MHCC Web resentation proposal-3-19-2012-published
2012 MHCC Web resentation proposal-3-19-2012-published
Â
PolyMedix ($PYMX) Cowan Research
PolyMedix ($PYMX) Cowan Research
Â
VTUS Cowen Final March 2012
VTUS Cowen Final March 2012
Â
KĂŒrzlich hochgeladen
@9999965857 đ«Š Sexy Desi Call Girls Karol Bagh đ High Profile Escorts Delhi đ«¶
@9999965857 đ«Š Sexy Desi Call Girls Karol Bagh đ High Profile Escorts Delhi đ«¶
Call Girls In Delhi Whatsup 9873940964 Enjoy Unlimited Pleasure
Â
Russian Call Girls Kolkata Indira đ€ 8250192130 đ Vip Call Girls Kolkata
Russian Call Girls Kolkata Indira đ€ 8250192130 đ Vip Call Girls Kolkata
anamikaraghav4
Â
Sustainability Leadership, April 26 2024
Sustainability Leadership, April 26 2024
TeckResourcesLtd
Â
Methanex Investor Presentation (April 2024)
Methanex Investor Presentation (April 2024)
Methanex Corporation
Â
ćŠäœćçćŁäœćĄć·ç«ć€§ćŠæŻäžèŻ(æć)SJSUćŠäœèŻäčŠ
ćŠäœćçćŁäœćĄć·ç«ć€§ćŠæŻäžèŻ(æć)SJSUćŠäœèŻäčŠ
Fir La
Â
ćŠäœćçćŻèé性ćŠć ȘèšæŻćæ ĄæŻäžèŻ(æć)UMKCćŠäœèŻäčŠ
ćŠäœćçćŻèé性ćŠć ȘèšæŻćæ ĄæŻäžèŻ(æć)UMKCćŠäœèŻäčŠ
Fir La
Â
ćŠäœćçććĄçœæ„çșłć€§ćŠæć ć±±ćæ ĄæŻäžèŻ(æć)UNCćŠäœèŻäčŠ
ćŠäœćçććĄçœæ„çșłć€§ćŠæć ć±±ćæ ĄæŻäžèŻ(æć)UNCćŠäœèŻäčŠ
Fir La
Â
The Concept of Humanity in Islam and its effects at future of humanity
The Concept of Humanity in Islam and its effects at future of humanity
JohanAspro
Â
Falcon Invoice Discounting - Best Platform
Falcon Invoice Discounting - Best Platform
Falcon Invoice Discounting
Â
High Profile Call Girls Kolkata Trisha đ€ 8250192130 đ Vip Call Girls Kolkata
High Profile Call Girls Kolkata Trisha đ€ 8250192130 đ Vip Call Girls Kolkata
anamikaraghav4
Â
Collective Mining | Corporate Presentation - April 2024
Collective Mining | Corporate Presentation - April 2024
CollectiveMining1
Â
VIP 7001035870 Find & Meet Hyderabad Call Girls Miyapur high-profile Call Girl
VIP 7001035870 Find & Meet Hyderabad Call Girls Miyapur high-profile Call Girl
aditipandeya
Â
Model Call Girl in Uttam Nagar Delhi reach out to us at đ9953056974đ
Model Call Girl in Uttam Nagar Delhi reach out to us at đ9953056974đ
9953056974 Low Rate Call Girls In Saket, Delhi NCR
Â
Call Girls đ«€ Nehru Place âĄïž 9999965857 âĄïž Delhi đ«Š Russian Escorts FULL ENJOY
Call Girls đ«€ Nehru Place âĄïž 9999965857 âĄïž Delhi đ«Š Russian Escorts FULL ENJOY
Call Girls In Delhi Whatsup 9873940964 Enjoy Unlimited Pleasure
Â
Model Call Girl in Udyog Vihar Delhi reach out to us at đ9953056974đ
Model Call Girl in Udyog Vihar Delhi reach out to us at đ9953056974đ
9953056974 Low Rate Call Girls In Saket, Delhi NCR
Â
Escort Service Call Girls In Shalimar Bagh, 99530°56974 Delhi NCR
Escort Service Call Girls In Shalimar Bagh, 99530°56974 Delhi NCR
9953056974 Low Rate Call Girls In Saket, Delhi NCR
Â
9654467111 Low Rate Call Girls In Tughlakabad, Delhi NCR
9654467111 Low Rate Call Girls In Tughlakabad, Delhi NCR
Sapana Sha
Â
Osisko Gold Royalties Ltd - Corporate Presentation, April 23, 2024
Osisko Gold Royalties Ltd - Corporate Presentation, April 23, 2024
Osisko Gold Royalties Ltd
Â
OKC Thunder Reveal Game 2 Playoff T Shirts
OKC Thunder Reveal Game 2 Playoff T Shirts
rahman018755
Â
ăć ć·ć€§ćŠćŁć éČć čćæ ĄćŠäœèŻäčŠć€ć¶ăQćŸźäżĄ741003700çŸćœćŠćçéŸéźéąæć|æç§èą«ć ć·ć€§ćŠćŁć éČć čćæ ĄćéæČĄææŻäžèŻæäčć?ăUCSCæŻäžèŻèŽäč°|ć ...
ăć ć·ć€§ćŠćŁć éČć čćæ ĄćŠäœèŻäčŠć€ć¶ăQćŸźäżĄ741003700çŸćœćŠćçéŸéźéąæć|æç§èą«ć ć·ć€§ćŠćŁć éČć čćæ ĄćéæČĄææŻäžèŻæäčć?ăUCSCæŻäžèŻèŽäč°|ć ...
wyqazy
Â
KĂŒrzlich hochgeladen
(20)
@9999965857 đ«Š Sexy Desi Call Girls Karol Bagh đ High Profile Escorts Delhi đ«¶
@9999965857 đ«Š Sexy Desi Call Girls Karol Bagh đ High Profile Escorts Delhi đ«¶
Â
Russian Call Girls Kolkata Indira đ€ 8250192130 đ Vip Call Girls Kolkata
Russian Call Girls Kolkata Indira đ€ 8250192130 đ Vip Call Girls Kolkata
Â
Sustainability Leadership, April 26 2024
Sustainability Leadership, April 26 2024
Â
Methanex Investor Presentation (April 2024)
Methanex Investor Presentation (April 2024)
Â
ćŠäœćçćŁäœćĄć·ç«ć€§ćŠæŻäžèŻ(æć)SJSUćŠäœèŻäčŠ
ćŠäœćçćŁäœćĄć·ç«ć€§ćŠæŻäžèŻ(æć)SJSUćŠäœèŻäčŠ
Â
ćŠäœćçćŻèé性ćŠć ȘèšæŻćæ ĄæŻäžèŻ(æć)UMKCćŠäœèŻäčŠ
ćŠäœćçćŻèé性ćŠć ȘèšæŻćæ ĄæŻäžèŻ(æć)UMKCćŠäœèŻäčŠ
Â
ćŠäœćçććĄçœæ„çșłć€§ćŠæć ć±±ćæ ĄæŻäžèŻ(æć)UNCćŠäœèŻäčŠ
ćŠäœćçććĄçœæ„çșłć€§ćŠæć ć±±ćæ ĄæŻäžèŻ(æć)UNCćŠäœèŻäčŠ
Â
The Concept of Humanity in Islam and its effects at future of humanity
The Concept of Humanity in Islam and its effects at future of humanity
Â
Falcon Invoice Discounting - Best Platform
Falcon Invoice Discounting - Best Platform
Â
High Profile Call Girls Kolkata Trisha đ€ 8250192130 đ Vip Call Girls Kolkata
High Profile Call Girls Kolkata Trisha đ€ 8250192130 đ Vip Call Girls Kolkata
Â
Collective Mining | Corporate Presentation - April 2024
Collective Mining | Corporate Presentation - April 2024
Â
VIP 7001035870 Find & Meet Hyderabad Call Girls Miyapur high-profile Call Girl
VIP 7001035870 Find & Meet Hyderabad Call Girls Miyapur high-profile Call Girl
Â
Model Call Girl in Uttam Nagar Delhi reach out to us at đ9953056974đ
Model Call Girl in Uttam Nagar Delhi reach out to us at đ9953056974đ
Â
Call Girls đ«€ Nehru Place âĄïž 9999965857 âĄïž Delhi đ«Š Russian Escorts FULL ENJOY
Call Girls đ«€ Nehru Place âĄïž 9999965857 âĄïž Delhi đ«Š Russian Escorts FULL ENJOY
Â
Model Call Girl in Udyog Vihar Delhi reach out to us at đ9953056974đ
Model Call Girl in Udyog Vihar Delhi reach out to us at đ9953056974đ
Â
Escort Service Call Girls In Shalimar Bagh, 99530°56974 Delhi NCR
Escort Service Call Girls In Shalimar Bagh, 99530°56974 Delhi NCR
Â
9654467111 Low Rate Call Girls In Tughlakabad, Delhi NCR
9654467111 Low Rate Call Girls In Tughlakabad, Delhi NCR
Â
Osisko Gold Royalties Ltd - Corporate Presentation, April 23, 2024
Osisko Gold Royalties Ltd - Corporate Presentation, April 23, 2024
Â
OKC Thunder Reveal Game 2 Playoff T Shirts
OKC Thunder Reveal Game 2 Playoff T Shirts
Â
ăć ć·ć€§ćŠćŁć éČć čćæ ĄćŠäœèŻäčŠć€ć¶ăQćŸźäżĄ741003700çŸćœćŠćçéŸéźéąæć|æç§èą«ć ć·ć€§ćŠćŁć éČć čćæ ĄćéæČĄææŻäžèŻæäčć?ăUCSCæŻäžèŻèŽäč°|ć ...
ăć ć·ć€§ćŠćŁć éČć čćæ ĄćŠäœèŻäčŠć€ć¶ăQćŸźäżĄ741003700çŸćœćŠćçéŸéźéąæć|æç§èą«ć ć·ć€§ćŠćŁć éČć čćæ ĄćéæČĄææŻäžèŻæäčć?ăUCSCæŻäžèŻèŽäč°|ć ...
Â
Intracoronary Bone Marrow Mononuclear Cells After Myocardial Infarction
1.
LETTERS Intracoronary Bone Marrow
Mononuclear Cells to âguard against both premature declarations of victory After Myocardial Infarction and premature abandonment of a promising therapeutic strategy.â5 To the Editor: The LateTIME trial findings1 suggest a lack Hung Q. Ly, MD, MSc, FRCPC of benefit from intracoronary delivery of bone marrow mono- Author Affiliation: Interventional Cardiology Division, Montreal Heart Institute, nuclear cells (BMCs) 2 to 3 weeks after primary percuta- Universite de Montreal, Montreal, Quebec, Canada (Qh.ly@montreal.ca). ÂŽ ÂŽ neous coronary intervention (PCI) in patients with myo- Conflict of Interest Disclosures: The author has completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and reported receiving grants cardial infarction (MI) and depressed left ventricular (LV) from the Fonds de Recherche en Sante du Quebec, the TheCell Network, the Ca- ÂŽ ÂŽ ÂŽ function. However, further clarification is needed to better nadian Stem Cell Network, the Heart and Stroke Foundation of Canada, the Mon- treal Heart Institute Foundation, and the DesGroseillers-Berard-Universite de Mon- ÂŽ ÂŽ appreciate the study conclusions. treal Chair in Interventional Cardiology; and serving as a consultant to Cook Medical. ÂŽ While timing can affect efficacy of cardiac cell-based 1. Traverse JH, Henry TD, Ellis SG, et al; Cardiovascular Cell Therapy Research therapies, patient selection remains of paramount impor- Network (CCTRN). Effect of intracoronary delivery of autologous bone marrow tance. It is unclear why patients with lesions in coronary mononuclear cells 2 to 3 weeks following acute myocardial infarction on left ven- tricular function: the LateTIME randomized trial. JAMA. 2011;306(19):2110- arteries other than the left anterior descending (4 right 2119. coronary arteries and 1 left circumflex coronary artery, all 2. Ly HQ, Hoshino K, Pomerantseva I, et al. In vivo myocardial distribution of mul- tipotent progenitor cells following intracoronary delivery in a swine model of myo- in the intervention group) were included. Because the cardial infarction. Eur Heart J. 2009;30(23):2861-2868. mean qualifying LV ejection fraction (LVEF) was 35% to 3. Meyer GP, Wollert KC, Lotz J, et al. Intracoronary bone marrow cell transfer 36%, could a mixed cardiomyopathy have explained the after myocardial infarction: 5-year follow-up from the randomized-controlled BOOST trial. Eur Heart J. 2009;30(24):2978-2984. initial LV dysfunction and thus partly biased the efficacy 4. Eitel I, Kubusch K, Strohm O, et al. Prognostic value and determinants of a hy- findings in cell-treated patients? Moreover, was consider- pointense infarct core in T2-weighted cardiac magnetic resonance in acute rep- erfused ST-elevation-myocardial infarction. Circ Cardiovasc Imaging. 2011; ation given to including only patients with anterior wall 4(4):354-362. MIs associated with severe but persistent LV dysfunction 5. Rosenzweig A. Cardiac cell therapyâmixed results from mixed cells. N Engl J Med. 2006;355(12):1274-1277. (ie, LVEF Ő 35% at baseline and not just at screening), who would be more likely to benefit from BMC injection To the Editor: Dr Traverse and colleagues observed no dif- relative to a population with only moderate LV impair- ferences at 6 months in global or regional LV function, ment? While more likely to induce recruitment delays, infarct size, or infarct volumes in patients with LV dys- such a strategy might have resulted in greater benefit in function as a consequence of an MI who received intra- the intervention group. coronary infusion of autologous BMCs compared with As mentioned by Dr Traverse and colleagues, other cell controls.1 The authors attributed the lack of efficacy when populations (bone marrowâderived or not) could ulti- compared with similar trials that found an improvement in mately prove more beneficial in such a clinical setting. How- LV function in part to the late time of infusion (median: ever, alternative routes of delivery, such as intramyocar- 17.4 days vs 7 days in prior studies) when BMC homing dial or transcoronary, might prove to be more efficacious. signals from ischemic cardiomyocytes have diminished. Although intracoronary injection remains a widely used We believe the authors did not address a more likely cause method, it is associated with poor rates of cell retention.2 for lack of efficacy in their trial: infusion of an insufficient In addition, the Bone Marrow Transfer to Enhance ST- number of potent cells. Elevation Infarct Regeneration (BOOST) investigators, in their long-term follow-up analysis,3 reported that mag- GUIDELINES FOR LETTERS. Letters discussing a recent JAMA article should netic resonance imaging (MRI) characterization of myocar- be submitted within 4 weeks of the articleâs publication in print. Letters received dial damage suggested subgroups that may have a greater after 4 weeks will rarely be considered. Letters should not exceed 400 words of text and 5 references and may have no more than 3 authors. Letters reporting clinical response to cardiac cell-based therapies. Were dif- original research should not exceed 600 words of text and 6 references and may ferences observed in intramyocardial hemorrhage, trans- have no more than 5 authors. They may include up to 2 tables or figures but on- mural infarction, or microvascular obstruction between line supplementary material is not allowed. All letters should include a word count. Letters must not duplicate other material published or submitted for publication. groups in this study? Such MRI characteristics reflect an al- Letters not meeting these specifications are generally not considered. Letters will tered course in myocardial salvage and LV remodeling4 and be published at the discretion of the editors and are subject to abridgement and editing. Further instructions can be found at http://jama.com/instructions. A signed therefore might modulate the effects of cardiac cell-based statement for authorship criteria and responsibility, financial disclosure, copyright therapies. transfer, and acknowledgment and the ICMJE Form for Disclosure of Potential Con- flicts of Interest are required before publication. Letters should be submitted via It will be challenging for any adjunctive therapeutic strat- the JAMA online submission and review system at http://manuscripts.jama.com egy to show an incremental benefit in morbidity or mortal- (note: do not include âwwwâ before the URL). For technical assistance, please ity above that of the well-established clinical success of pri- contact jama-letters@jama-archives.org. mary PCI. Nevertheless, the LateTIME study will contribute Letters Section Editor: Jody W. Zylke, MD, Senior Editor. 1022 JAMA, March 14, 2012âVol 307, No. 10 ©2012 American Medical Association. All rights reserved. Downloaded from jama.ama-assn.org at American Medical Association on March 14, 2012
2.
LETTERS
The potency of intracoronary-infused BMCs appears to ment, but only 5 patients had nonâanterior MIs. Their in- depend on the number of CD34 cells (a subset of BMCs) clusion did not appear to influence outcomes because the infused and the mobility of CD34 cells measured in vitro results were similar when analyzed without these patients. in a stromal-derived factor 1 (SDF-1) gradient. A meta- We have no evidence suggesting our patients had other forms analysis of 811 patients with MI demonstrated the impor- of cardiomyopathy contributing to the reduced LVEF on tance of the number of cells infused because the greatest im- qualifying echocardiogram (mean [SD], 36.4% [6.5%]) provement in LV function and volumes were observed among within 48 hours of their PCI. When measured at the time patients receiving more than 109 BMCs.2 In addition to quan- of the intracoronary infusion several weeks later, LVEF had tity, Britten et al3 observed that the ex vivo migratory ca- increased (mean [SD], 44.3% [8.4%]) likely due to resolu- pacity of BMCs (the migratory subset being CD34 cells co- tion of myocardial stunning. Still, it remained below the base- expressing CXCR-4 receptors) in an SDF-1 gradient was the line median of 48.9% seen in the Reinfusion of Enriched Pro- strongest independent predictor of LV infarct size reduc- genitor Cells and Infarct Remodeling in Acute Myocardial tion after intracoronary infusion of BMCs. Seeger et al4 later Infarction (REPAIR-AMI) study in which the greatest ben- showed preparing BMCs in heparin and saline, and not au- efit of BMCs on LVEF recovery was observed.1 We agree that tologous serum without heparin, significantly reduced SDF-1 patients with persistent LV dysfunction after MI (LVEF mobility. Our study of intracoronary infused purified CD34 Ïœ35%) constitute an important target for future studies that cells demonstrated that a minimum of 10Ï« 106 CD34 cells should include new cell types and delivery methods such was required to improve perfusion and again showed a sig- as intramyocardial or transcoronary delivery. We are cur- nificant positive correlation between the number of mobile rently performing more detailed MRI analyses to address the (measured in an SDF-1 gradient) CD34 cells infused and extent of infarct transmurality and microvascular obstruc- improvement in perfusion and decrease in infarct size.5 tion that may also influence outcomes. In the LateTIME trial, treated patients received a median Drs Quyyumi and Pecora speculate that insufficient cell CD34 cell dose of 3.8 ± 1.5Ï« 106 cells, well below 10Ï« 106 numbers may have caused lack of efficacy, note the role of CD34 cells. Additionally, in vitro SDF-1 mobility of the in- heparin, and state that âin vitro SDF-1 mobility of the in- fused cells was not measured and may have been adversely fused cells was not measured.â The latter statement is in- affected by the absence of autologous serum in the infused correct because SDF-1 mobility, as well as nitric oxide pro- product. Future studies must account for the quantity and duction and other measures, are part of our biorepository mobility of infused (potent) cells before conclusions re- studies2 to develop mechanistic insights into cardiovascu- garding efficacy are made. lar cell therapy. These studies are ongoing and beyond the Arshed Quyyumi, MD, FRCP scope of the clinical results presented in our article. Andrew L. Pecora, MD Our delivered dose exceeded the greater than 100 million BMC threshold identified by meta-analysis to be efficacious,3 Author Affiliations: Division of Cardiology, Emory University, Atlanta, Georgia (Dr Quyyumi); and John Theurer Cancer Center, Hackensack University Medical Cen- and the number of CD34 cells infused was similar to the ter, Hackensack, New Jersey (Dr Pecora) (apecora@humed.com). REPAIR-AMI trial, which had a positive outcome.1 Different Conflict of Interest Disclosures: The authors have completed and submitted the cell isolation procedures generate different BMC numbers (re- ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Quyyumi reported being a consultant to Amorcyte. Dr Pecora reported being chief medical officer of covery), composition, and function (colony assays and in- NeoStem (manufacturer and equity owner of Amorcyte). vivo angiogenesis), but the specific details responsible for these 1. Traverse JH, Henry TD, Ellis SG, et al; Cardiovascular Cell Therapy Research differences are unclear. Possibilities include, but are not lim- Network (CCTRN). Effect of intracoronary delivery of autologous bone marrow ited to, heparin concentration, density gradient medium, cen- mononuclear cells 2 to 3 weeks following acute myocardial infarction on left ven- tricular function: the LateTIME randomized trial. JAMA. 2011;306(19):2110- trifuge speed and time, wash steps (number, diluents, and cen- 2119. trifuge settings), overnight storage, and red blood cell content. 2. Martin-Rendon E, Brunskill SJ, Hyde CJ, Stanworth SJ, Mathur A, Watt SM. Autologous bone marrow stem cells to treat acute myocardial infarction: a sys- With so many variables, head-to-head comparisons are re- tematic review. Eur Heart J. 2008;29(15):1807-1818. quired to determine specific contributions. Our final cell sus- 3. Britten MB, Abolmaali ND, Assmus B, et al. Infarct remodeling after intracoro- nary progenitor cell treatment in patients with acute myocardial infarction (TOPCARE- pension volume contained very little heparin (after 3 washes, AMI): mechanistic insights from serial contrast-enhanced magnetic resonance the 43 mL of cell suspension contained 0.49 units of heparin imaging. Circulation. 2003;108(18):2212-2218. total) and was not stored overnight. We are not aware of re- 4. Seeger FH, Tonn T, Krzossok N, Zeiher AM, Dimmeler S. Cell isolation proce- dures matter: a comparison of different isolation protocols of bone marrow mono- ports directly addressing heparinâs effect on BMC migration. nuclear cells used for cell therapy in patients with acute myocardial infarction. Eur The study by Seeger et al4 tested 2 cell separation protocols Heart J. 2007;28(6):766-772. 5. Quyyumi AA, Waller EK, Murrow J, et al. CD34(Ï©) cell infusion after ST el- with many variables and did not directly measure the effects evation myocardial infarction is associated with improved perfusion and is dose of heparin. In addition, heparin expanded the number of he- dependent. Am Heart J. 2011;161(1):98-105. matopoietic progenitor cells in an umbilical cord blood study, In Reply: We support Dr Lyâs comments on the impor- illustrating the complexity of this issue.5 tance of patient selection in these trials. We elected to in- Therefore, we believe the timing of BMC delivery after clude patients with large infarcts from lesions in nonâleft MI remains a critical factor in the results of the LateTIME anterior descending coronary arteries to facilitate enroll- trial. The results of the TIME trial,6 available later this year, ©2012 American Medical Association. All rights reserved. JAMA, March 14, 2012âVol 307, No. 10 1023 Downloaded from jama.ama-assn.org at American Medical Association on March 14, 2012
3.
LETTERS will provide insights
into the results of delivery on day 3 low separate analyses of clopidogrel escalating doses by dia- compared with day 7 after MI. betes status in carriers and noncarriers. Jay H. Traverse, MD Patients with chronic kidney disease frequently present with Timothy D. Henry, MD increased platelet reactivity, and worse renal function dimin- Carl J. Pepine, MD ishes the platelet inhibitory effect of clopidogrel.3 In the PLATO Author Affiliations: Minneapolis Heart Institute Foundation at Abbott Northwest- trial, ticagrelor compared with clopidogrel resulted in a greater ern Hospital, Minneapolis, Minnesota (Drs Traverse and Henry) (Jay.Traverse absolute risk reduction in patients with chronic kidney dis- @allina.com); and University of Florida College of Medicine, Gainesville (Dr Pep- ine), for the Cardiovascular Cell Therapy Research Network. ease than in those with normal renal function.4 It would be Conflict of Interest Disclosures: The authors have completed and submitted the interesting to know if impaired renal function differentially ICMJE Form for Disclosure of Potential Conflicts of Interest. Drs Traverse, Henry, affected the improvement in platelet inhibition with increas- and Pepine reported receiving grants, travel support, and research support to their institutions from the National Heart, Lung, and Blood Institute. Dr Pepine also re- ing doses of clopidogrel between carriers and noncarriers. ported receiving research support to his institution from BDS Cordis Corp- We agree with the authorsâ suggestion of alternate anti- (NOGA) and serving on the scientific advisory board for Amorcyte. platelet agent use in cases of low or nonresponsiveness to 1. Schachinger V, Erbs S, Elsasser A, et al; REPAIR-AMI Investigators. Intracoro- š š clopidogrel in carriers of CYP2C19*2 loss-of-function al- nary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med. 2006;355(12):1210-1221. lele. We found that prasugrel was superior to a double dose 2. Zierold C, Carlson MA, Obodo UC, et al. Developing mechanistic insights into of clopidogrel, particularly in carriers of the CYP2C19*2 loss- cardiovascular cell therapy: Cardiovascular Cell Therapy Research Network Bio- repository Core Laboratory rationale. Am Heart J. 2011;162(6):973-980. of-function allele.5 3. Martin-Rendon E, Brunskill SJ, Hyde CJ, Stanworth SJ, Mathur A, Watt SM. Autologous bone marrow stem cells to treat acute myocardial infarction: a sys- Dimitrios Alexopoulos, MD, FACC, FESC tematic review. Eur Heart J. 2008;29(15):1807-1818. Ioanna Xanthopoulou, MD 4. Seeger FH, Tonn T, Krzossok N, Zeiher AM, Dimmeler S. Cell isolation proce- dures matter: a comparison of different isolation protocols of bone marrow mono- Author Affiliations: Department of Cardiology, Patras University Hospital, Rio, Pa- nuclear cells used for cell therapy in patients with acute myocardial infarction. Eur tras, Greece (dalex@med.upatras.gr). Heart J. 2007;28(6):766-772. Conflict of Interest Disclosures: The authors have completed and submitted the 5. Okamoto T, Takagi M, Soma T, et al. Effect of heparin addition on expansion ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Alexopoulos re- of cord blood hematopoietic progenitor cells in three-dimensional coculture with ported receiving speaker fees from sanofi-aventis, Pharmaserve, Eli Lilly, Astra- stromal cells in nonwoven fabrics. J Artif Organs. 2004;7(4):194-202. Zeneca, and Boehringer Ingelheim. Dr Xanthopoulou reported no disclosures. 6. Traverse JH, Henry TD, Vaughan DE, et al; Cardiovascular Cell Therapy Re- search Network (CCTRN). Rationale and design for TIME: a phase II, randomized, 1. Mega JL, Hochholzer W, Frelinger AL III, et al. Dosing clopidogrel based on double-blind, placebo-controlled pilot trial evaluating the safety and effect of tim- CYP2C19 genotype and the effect on platelet reactivity in patients with stable car- ing of administration of bone marrow mononuclear cells after acute myocardial diovascular disease. JAMA. 2011;306(20):2221-2228. infarction [published correction appears in Am Heart J. 2009;158(6):1045]. Am 2. Wallentin L, James S, Storey RF, et al; PLATO investigators. Effect of CYP2C19 Heart J. 2009;158(3):356-363. and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ti- cagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet. 2010;376(9749):1320-1328. Clopidogrel Dosing Based on Genotype 3. Htun P, Fateh-Moghadam S, Bischofs C, et al. Low responsiveness to clopido- grel increases risk among CKD patients undergoing coronary intervention. J Am To the Editor: Dr Mega and colleagues1 presented a study Soc Nephrol. 2011;22(4):627-633. 4. James S, Budaj A, Aylward P, et al. Ticagrelor versus clopidogrel in acute coro- showing that increasing the clopidogrel dose resulted in plate- nary syndromes in relation to renal function: results from the Platelet Inhibition let inhibitory effects in patients heterozygous for the and Patient Outcomes (PLATO) trial. Circulation. 2010;122(11):1056-1067. 5. Alexopoulos D, Dimitropoulos G, Davlouros P, et al. Prasugrel overcomes high CYP2C19*2 loss-of-function allele, but not in homozy- on-clopidogrel platelet reactivity post-stenting more effectively than high-dose (150- gotes. We consider a few points that require clarification. mg) clopidogrel: the importance of CYP2C19*2 genotyping. JACC Cardiovasc Interv. 2011;4(4):403-410. Platelet reactivity was assessed at least 1 month after myo- cardial infarction (MI), percutaneous coronary interven- In Reply: Drs Alexopoulos and Xanthopoulou ask about the tion (PCI), or both. However, it is well recognized that most timing of the intervention in ELEVATE-TIMI 56 relative to events, including stent thrombosis, occur early, within 30 the patientsâ clinical course. The aim of ELEVATE-TIMI 56 days of PCI. In the Platelet Inhibition and Patient Out- was to evaluate whether higher maintenance doses of clopi- comes (PLATO) genetic substudy,2 the event rate at 30 days dogrel could improve the pharmacological response in the set- was higher in clopidogrel-treated patients with CYP2C19 ting of loss-of-function CYP2C19 genotypes. Thus, by de- alleles than those without CYP2C19 alleles, leading to ear- sign, patients were in the maintenance phase of P2Y12 adenosine lier separation of event rates between the ticagrelor and clopi- diphosphate (ADP) receptor blockade therapy and were en- dogrel groups in patients with loss-of-function alleles. In con- rolled between 4 weeks and 6 months following PCI or acute trast, beyond 30 days, no difference in event rates between MI. Clinical circumstances such as PCI or acute MI can affect treatment groups for patients with any loss-of-function al- platelet reactivity. Therefore, the protocol specified that en- lele was observed. Therefore, genotyping and appropriate rollment should occur at a time in which platelet reactivity clopidogrel dose escalation outside the setting of MI and PCI should have stabilized to minimize the risk of these clinical may not provide incremental clinical utility. circumstances influencing results with the different doses of Diabetes mellitus is widely accepted as a major adverse clopidogrel, which were administered in various temporal se- clinical factor affecting platelet reactivity. In the present study, quences. The findings in ELEVATE-TIMI 56, which evalu- 35.4% (36.4% in noncarriers and 32.6% in carriers) of pa- ated maintenance doses of clopidogrel, are consistent with the tients had diabetes, a sample probably large enough to al- findings of the Clopidogrel and Response Variability Investi- 1024 JAMA, March 14, 2012âVol 307, No. 10 ©2012 American Medical Association. All rights reserved. Downloaded from jama.ama-assn.org at American Medical Association on March 14, 2012
Jetzt herunterladen